MASLD/MASH & Cirrhosis
LiverMultiScan
Our cutting-edge, multiparametric MRI technology capabilities allow us to non-invasively characterize liver health by providing comprehensive measurements of liver fat, iron concentration, fibro-inflammation and more.
cT1 and MRI-PDFF have been shown to have high correlation with histological measures of fibrosis, inflammation, and steatosis. cT1 has been shown to reliably predict liver and cardiac clinical outcomes with an 80 ms change recognized as clinically significant.
Enhanced patient screening
Reduce screen fail rates, improve patient experience, and lower trial costs by pre-screening with our best-in-class imaging biomarkers before the initial biopsy.The histological features that contribute to steatohepatitis, including liver fat, fibrosis, and inflammation, can be characterized using MRI-PDFF and cT1.
Standardized and reproducible results
cT1 and MRI-PDFF have excellent reproducibility and repeatability with superior diagnostic accuracy. This enables reliable monitoring of disease progression and treatment response, allowing trials to be run with more confidence.cT1 corrects for iron content, field strength, and manufacturer differences, enabling and supporting large scale multi-site trials.
Monitoring with cT1
cT1 accurately detects early efficacy signals and pseudo-progression, and quantitatively monitors drug-induced liver injury.
Digital pathology
Our digital pathology solution combines rapid, high-quality sample processing with a fully digitized reporting workflow and quantitative AI-pathology. It removes unnecessary shipping steps and enables multiple pathologists to report cases in parallel through a best-in-class digital viewing and eCRF-style reporting platforms.Combined with industry-leading three-day sample processing, and fully automated report generation, our solution allows reports to be delivered to clinical sites in as little as ten business days from receipt of tissue.
.png)
Customer feedback
"The workflow is the most intuitive and user-friendly system I’ve worked with"
- Study pathologist in a phase 3 NASH study
"A lot of companies try to change the way I report to fit their workflow, you’ve built a system that fits the way I already report"
- NASH CRN pathologist
"We're happy with the service and the pathologists love the reporting system"
- Medical Director phase 3 NASH trial
Quantifiable treatment response
AI-generated metrics provide a robust and reproducible method to quantify disease features. Gain insights into finer degrees of treatment response using our continuous AI-metrics:
- % Steatosis
- % Inflammatory burden and number of foci per mm2
- Total number of ballooned hepatocytes and number of ballooned hepatocytes per mm2
- % Collagen Proportionate Area (CPA)
Esophagogastroduodenoscopy (EGD)
Our endoscopy central reading service supports both still images and HD videos. Our eCRF-style reporting templates, AI-enhanced quality checks, and customizable consensus and adjudication workflows enhance the reporting experience for central readers and reduce turnaround times.HD recording equipment can be provided to sites to ensure standardized, high-quality data is collected in large-scale, multi-center studies.
